Inhibitors of multidrug resistant efflux systems in bacteria

Recent Patents on Anti-Infective Drug Discovery

Volumn 4, Issue 1, 2009, Pages 37-50

  Zechini, Barbara ^a   Versace, Ilaria ^a  

^a Aurelia Hospital   (Italy)

Author keywords

Antibiotic efflux; Bacterial resistance; Efflux pump inhibitors; Efflux system; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BIRICODAR; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; EFFLUX PUMP INHIBITOR; ERYTHROMYCIN; FLORFENICOL; GLYCYLCYCLINE DERIVATIVE; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MC 207 110; MC 601 205; MULTIDRUG RESISTANCE PROTEIN 1; NORFLOXACIN; OMEPRAZOLE; OXAZOLIDINE DERIVATIVE; PENICILLIN G; PHENYLALANINE ARGINYL BETA NAPHTHYLAMINE; PROMETHAZINE; PROTON PUMP INHIBITOR; QUINAZOLINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; STREPTOGRAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ANTIINFECTIVE AGENT; CARRIER PROTEIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL METABOLISM; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; DRUG DESIGN; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; BACTERIUM; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MEMBRANE TRANSPORT PROTEINS;

EID: 62749178622     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489109787236256     Document Type: Review

References (139)

1. Webber MA, Piddock LVJ. The importance of efflux pumps in antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11.
2. Li HZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64: 159-204.
3. Piddock LV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
4. Stavri M, Piddock LJW, Gibbons S. Bacterial efflux pumps from natural sources. J Antimicrob Chemother 2007; 59: 1247-1260.
5. Levy SB. Active efflux, a common mechanism for biocide and antibiotic resistance. J Appl Microbiol 2002; 92 (Suppl): 65S-71S.
6. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51.
7. Saier MH Jr, Paulsen IT. Phylogeny of multidrug transporters. Semin Cell Dev Biol 2001; 12: 205-213.
8. Marquez B. Bacterial efflux system and efflux pump inhibitors. Biochimie 2005; 87: 1137-1147.
9. Lynch AS. Efflux systems in bacterial pathogens: An opportunity for therapeutic intervention? An industry view. Biochem Pharmacol 2006; 71: 949-956.
10. Pagès JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 2005; 11: 382-389.
11. Chang G. Multidrug resistance ABC transporters. FEBS Lett 2003; 555: 102-105.
12. Lage H. ABC-transporters: Implications on drug resistance from microorganisms to human cancer. Int J Antimicrob Agents 2003; 22: 188-199.
13. Higgins CF. ABC transporters: Physiology, structure, and mechanism- an overview. Res Microbiol 2001; 152: 205-210.
14. Mèndez C, Salas JA. The role of ABC transporters in antibiotic-producing organisms: Drug secretion and resistance mechanism. Res Microbiol 2001; 152: 341-352.
15. Ross JI, Eady EA, Cove JH, Cunliffe WJ, Baumberg S, Wooton JC. Inducible erythromycin resistance in Staphylococci is encoded by a member of ATP-binding transporter super-gene family. Mol Microbiol 1990; 4: 1207-1214.
16. Mansom JM, Keis S, Smith JMB, Cook GM. Acquired bacitracin resistance in Enterococcus faecalis is mediated by an ABC transporter and a novel regulatory protein, BcrR. Antimicrob Agents Chemother 2004; 48: 3743-3748.
17. Poelarends GJ, Mazurkiewicz P, Konings WN. Multidrug transporters and antibiotic resistance in Lactococcus lactis. Biochim Biophys Acta 2002; 1555: 1-7.
18. Lee RW, Huda MN, Kuroda T, Mizushima T, Tsuchiya T. EfrAB, an ABC multidrug efflux in pump in Enterococcus faecalis. Antimicrob Agents Chemother 2003; 47: 3733-3738.
19. Nuda N, Lee EW, Chen J, et al. Molecular cloning and characterisation of an ABC multidrug efflux pump, VcaM, in non-O1 Vibrio cholerae. Antimicrob Agents Chemother 2003; 47: 2413-2417.
20. Raherison S, Gonzales P, Renaudin H, Charron A, Bebear C, Bebear CM. Evidence of active efflux pump in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis. Antimicrob Agents Chemother 2002; 46: 672-679.
21. Saier MH, Beatty JT, Goffeau A, et al. The major facilitator superfamily. J Mol Microbiol Biotechnol 1999; 1: 257-279.
22. Tseng TT, Gratwick KS, Kollman J, et al. The RND permease superfamily: An ancient, ubiquitous and diverse family that includes human disease and development proteins. Mol Microbiol Biotechnol 1999; 1: 107-125.
23. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M. Nucleotide sequence and characterization of the Staphyloccus aureus NorA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942-6949.
24. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolones resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 187-189.
25. Lee EW, Chen J, Huda MN, Kuroda T, Mizushima T, Tsuchiya T. Functional cloning and expression of EmeA and characterization of EmeA, a multidrug efflux pump from Enterococcus faecalis. Biol Pharm Bull 2003; 26: 266-270.
26. Murakami S. Multidrug efflux transporter, AcrB-the pumping mechanism. Curr Opin Struct Biol 2008; 18: 459-465.
27. Chung YJ, Saier MH Jr. SMR-type multidrug resistance pumps. Curr Opin Drug Discov Dev 2001; 4: 237-245.
28. Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol Microbiol 1999; 31: 393-395.
29. Chollet R, Chevalier J, Bryskier A, Pages JM. The AcrAB-TolC pump is involved in macrolide resistance but not in thelitromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 2004; 48:3621-3624.
30. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003; 47: 1017-1022.
31. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigegycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-978.
32. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-669.
33. Pole K. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175: 7363-7372.
34. Pole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: Components, mechanisms and significance. Curr Top Med Chem 2001; 1: 59-71.
35. +-coupled multidrug efflux pump, PmpM, a member of the MATE family of transporters, from Pseudomonas aeruginosa. J Bacteriol 2004; 186: 262-265.
36. Yu EW, Aires JR, Nikaido H. AcrB multidrug efflux pump of Escherichia coli: Composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. J Bacteriol 2003; 185: 5657-5664.
37. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell-division-type efflux pump involved in aminoglycoside resistance in A cinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45: 3375-3380.
38. Eaves DJ, Ricci V, Piddock LJ. Expression of AcrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: Role in multiple antibiotic resistance. Antimicrob Agents Chemother 2004; 48: 1145-1150.
39. Pumbwe L, Piddock JV. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002; 206: 185-189.
40. Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. J Bacteriol 2002; 184: 5619-5624.
41. Pumbwe L, Chang A, Smith RL, Wexler HM. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacterioides fragilis isolates. J Antimicrob Chemother 2006; 58: 543-548.
42. Pradel E, Pages JM. The AcrB-TolC efflux pump contributes to multidrug resistance in nosocomial pathogen Enterobacter aerogenes. Antimicrob Agents Chemother 2002; 46: 2640-2643.
43. Mazzariol A, Zuliani J, Cornaglia G, Rossolini GM, Fontana R. AcrAB efflux system: Expression and contribution to fluoroquinolone resistance in Klebsiella spp. Antimicrob Agents Chemother 2002; 46: 3984-3986.
44. Kumar A, Worobec EA. Cloning, sequencing, and characterization of the SdeAB multidrug efflux pump of Serratia marcescens. Antimicrob Agents Chemother 2005; 49: 1495-1501.
45. Sanchez L, Pan W, Vinas M, Niakaido H. The AcrB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J Bacteriol 1997; 179: 6855-6857.
46. van Amsterdam K, Bart A, van der Ende A. A Helicobacter pylori TolC efflux pump confers resistance to metronidazole. Antimicrob Agents Chemother 2005, 49: 1477-1482.
47. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 1086-1094.
48. Truong-Bolduc QC, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 2005; 187: 2395-2405.
49. De Marco CE, Cushing LA, Frempong-Manso E, Seo SM, Jaravaza GA, Kaatz GW. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3235-3239.
50. Kaatz GW, McAleese F, Seo SM. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother 2005; 49: 1857-1864.
51. Robertson GT, Doyle TB, Lynch AS. Use of an efflux-deficient Streptococcus pneumoniae strain panel to identify ABC-class multiple transporters involved in intrinsic resistance to antimicrobial agents. Antimicrob Agents Chemother 2005; 49: 4781-4783.
52. Oyamada Y, Ito H, Inoue M, Yamagishi J. Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis. J Med Microbiol 2006; 55: 1395-1401.
53. Ly XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2004; 48: 2415-2423.
54. Pasca MR, Guglierame P, De Rossi E, Zara F, Riccardi G. mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Chemother 2005; 49: 4775-4777.
55. Colangeli R, Helb D, Sridharan S, et al. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 2005; 55:1829-1840.
56. De Rossi E, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 2006; 30: 36-52.
57. Ramón-García S, Martín C, De Rossi E, Aínsa JA. Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. J Antimicrob Chemother 2007; 59: 544-547.
58. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 2004; 28: 519-542.
59. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother 2008; 52: 2455-2462.
60. Hansen LH, Jensen LB, Sorensen HI, Sørensen SJ. Substrate specificity of the OqxAB multidrug resistance pump in Escherichia coli and selected enteric bacteria. J Antimicrob Chemother 2007; 60: 145-147.
61. Ge B, McDermott PF, White DG, Meng J. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005; 49: 3347-3354.
62. Kehrenberg C, Schwarz S. fex A, a novel Staphylococcus lentus gene encoding resistance to florfenicol and chloramphenicol. Antimicrob Agents Chemother 2004; 48: 615-618.
63. Pozzi G, Iannelli F, Oggioni MR, Santagatti M, Stefani S. Genetic elements carrying macrolide efflux genes in streptococci. Curr Drug Targets Infect Disord 2004; 4: 203-206.
64. Kobayashi N, Nishino K, Yamaguchi A. Novel macrolide-specific ABC-type efflux transporter in Escherichia coli. J Bacteriol 2001; 183: 5639-5644.
65. Gibreel A, Wetsch NM, Taylor DE. Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. Antimicrob Agents Chemother 2007; 51: 3212-3216.
66. Huang J, O'Toole PW, Shen W, et al. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 909-917.
67. Reynolds E, Ross JI, CoveJH. Msr(A) and related macrolide/streptogramin resistance determinants: Incomplete transporters? Int J Antimicrob Agents 2003; 22: 228-236.
68. Portillo A, Ruiz-Larrea F, Zarazaga M, Alonso A, Martinez JL, Torres C. Macrolide resistance genes in Enterococcus spp. Antimicrob Agents Chemother 2000; 44: 967-971.
69. Giovanetti E, Brenciani A, Burioni R, Varaldo PE. A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes. Antimicrob Agents Chemother 2002; 46: 3750-3755.
70. Dina J, Malbruny B, Leclercq R. Nonsense mutations in the lsa-like gene in Enterococcus faecalis isolates susceptible to lincosamides and streptogramins A. Antimicrob Agents Chemother 2003; 47: 2307-2309.
71. Butaye P, Cloeckaert A, Schwarz S. Mobile genes coding for efflux-mediated antimicrobial resistance in Gram-positive and Gram-negative bacteria. Int J Antimicrob Agents 2003; 22: 205-210.
72. Matsuo T, Chen J, Minato Y, et al. SmdAB, a heterodimeric ABC-Type multidrug efflux pump, in Serratia marcescens. J Bacteriol 2008; 190: 648-654.
73. McAleese F, Peterson P, Ruzin A, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Stophylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49: 1865-1871.
74. +-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother 2005; 49: 4362-4364.
75. Guglierame P, Pasca MR, De Rossi E, et al. Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome. BMC Microbiol 2006; 6: 66.
76. Chopra I. New development in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Update 2002; 5: 119-125.
77. Farrell DJ, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B) and mef(A) mediated macrolide resistance. J Clin Microbiol 2004; 42: 764-768.
78. Glinka, T., Bostian, K., Lomvskaya, O., Surber, M., Sun, D.: US20080076741 (2008).
79. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Inf Dis 2000; 31: S24-28.
80. Comita-Prevoir, J., Cronin, M., Geng, B., Godfrey, A.A., Reck, F.: WO2008071961 (2008).
81. Selvakumar, N., Das, J., Trehan, S., Iqbal, J., Kumar, M.S., Rajagopalan, R., Rao, M.N.V.S.: US20070004712A1 (2007).
82. Mahamoud A, Chevalier J, Libert-Franco S, Kern WV, Pages JM. Antibiotic efflux pumps in Gram negative bacteria: the inhibitory response strategy. J Antimicrob Chemother 2007; 59: 1223-1229.
83. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic - A vision for applied use. Biochem Pharmacol 2006; 71: 910-918.
84. Piddock LVJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006; 4: 629-636.
85. Mallea M, Chevalier J, Bornet C, et al. Porin alteration and active efflux: Two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 1998; 144: 3003-3009.
86. Brenwald N, Gill M, Wise R. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro susceptibilities of fluorquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin. J Antimicrob Chemother 1997; 40: 458-460.
87. Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 335-340.
88. Schmitz F, Fluit A, Luckefahr M, et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Sthapylococcus aureus. J Antimicrob Chemother 1998; 42: 807-810.
89. Gibbons S, Udo EE. The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) possessing the tet(K) determinant. Phytother Res 2000; 14: 139-140.
90. Vidaillac C, Guillon J, Arpin C, et al. Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of multidrug efflux pump NorA of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 831-838.
91. Molnar J, Hever A, Fakla I, Fisher J, Ocsovski I, Aszalos A. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in Escherichia coli and multidrug resistant tumor cells. Anticancer Res 1997; 17: 481-486.
92. Michalak K, Wesolowska O, Motohashi N, Molnar J, Hendrich AB. Interaction of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Curr Drug Targets 2006; 7: 1095-1105.
93. Martins M, Dastidar SG, Fanning S, et al. Potential role of non-antibiotics (helper compounds) in treatment of multidrug-resistant gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008; 31: 198-208.
94. Chan YY, Ong YM, Chua KL. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother 2007; 51: 623-630.
95. Lehtinen J, Lilius EM. Promethazine renders Escherichia coli susceptible to Penicillin G: Real-time measurement of bacterial susceptibility by fluoro-luminometry. Int J Antimicrob Agents 2007; 30: 44-51.
96. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-228.
97. Kolaczkowski M, Michalak K, Motohashi N. Phenothiazines as potent modulators of yeast multidrug resistance. Int J Antimicrob Agents 2003; 22: 279-283.
98. Oduola A, Sowunmi A, Milhous W, et al. in vitro and in vivo Reversal of chloroquine resistance in Plasmodium falciparum with promethazine. Am J Trop Med Hyg 1998; 58: 625-629.
99. Stermitz FR, Lorenz P, Tawara-Matsuda JN, Lorenz P, Muller P, Zenewicz LA. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. J Natl Acad Sci USA 2000; 97: 1433-1437.
100. Michalet S, Cartier G, David B, et al. N-Caffeoylphenalkylamide derivates as bacterial efflux pump inhibitors. Bioorg Med Chem Lett 2007; 17: 1755-1758.
101. Hasdemir UO, Chevalier J, Nordmann P, Pages JM. Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 2004; 42: 2701-2706.
102. Renau TE, Leger R, Flamme EM, et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluorquinolone antibacterial levofloxacin. J Med Chem 1999; 42: 4928-4931.
103. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother 2000; 44: 3441:3443.
104. Baucheron S, Imberechts H, Chaslus-Dancla E, Cloeckaert A. The AcrB multidrug transporters plasy a major role in high-level fluorquinolone resistance in Salmonella enterica serovar thyphimurium phage typer DT 204. Microb Drug Resist 2002; 8: 281-289.
105. Mallèa M, Chevalier J, Eyraud A, Pagès JM. Inhibitors of antibiotic efflux pumps in resistant Enterobacter aerogenes strains. Biochem Biophys Res Commun 2002; 293: 1370-1373.
106. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-116.
107. Coban AY, Ekinci AB, Durupinar B. A multidrug efflux inhibitor reduces fluorquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy 2004; 50: 22-26.
108. Mamelli L, Amoros JP, Pajès JM, Bolla JM. A phenylalaninearginine beta-napthylamide sensitive multidrug efflux pump involved in intrinsic and acquired resistance of Campylobacter to macrolides. Int J Antimicrob Agents 2003; 22: 237-241.
109. Renau TE, Leger R, Yen R, et al. Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 2002; 12: 763-766.
110. Watkins WJ, Landaverry Y, Leger R, et al. The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors. Bioorg Med Chem Lett 2003; 13: 4241-4244.
111. Yoshida K, Nakayama K, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: Highly soluble in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem 2007; 15: 7087-7097.
112. Thota N, Koul S, Reddy MV, et al. Citral derived amides as potent bacterial NorA efflux pump inhibitors. Bioorg Med Chem 2008; (in press) doi:10.1016/j.bmc.2008.05.030.
113. Mallea M, Mahamoud A, Chevalier J, et al. Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates. Biochem J 2003; 376: 801-805.
114. Chevalier J, Bredin J, Mahamaud A, Mallea M, Barbe J, Pages JM. Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother 2004; 48: 1043-1046.
115. Mahamoud A, Chevalier J, Davin-Regli A, Barbe J, Pagès JM. Quinolone derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes. Curr Drugs Targets 2006; 7: 843-847.
116. Watkins WJ, Lemoine RC, Chong L, et al. Quinazolinone fungal efflux pump inhibitors. Part 2: in vitro Structure-activity relationships of (N-methyl-piperazynil)-containing derivatives. Bioorg Med Chem Lett 2004; 14: 5133-5137.
117. German N, Wei P, Kaatz GW, Kerns RJ. Synthesis and evaluation of fluoroquinolones derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur J Med Chem 2008 (in press) doi: 10.1016/ j.ejmc.2008.01.042.
118. Munoz-Bellido JL, Munoz-Criado S, Garcia-Rodriguez JA. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J Antimicrob Agents 2000; 14: 177-180.
119. Kaatz GW, Moudgal VV, Seo SM, Hansen JB, Kristiansen JE. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int J Antimicrob Agents 2003; 22: 254-261.
120. German N, Kaatz GW, Kerns RJ. Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps. Bioorg Med Chem Lett 2008; 18: 1368-1373.
121. Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. Effect of 1-(1-naphtylmethyl)-piperazine, a novel putative efflux pumps inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chem 2006; 57: 339-343.
122. Thorarensen A, Presley Badnar AL, Marotti K, et al. Arylpiperidines as potentiators of existing antibacterial agents. Biorg Med Chem Lett 2001; 11: 1903-1906.
123. Pannek S, Higgins PG, Steinke P, et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-β-naphtylamide. J Antimicrob Chemother 2006, 57: 970-974.
124. Nelson, M.L., Alekshun, M.N.: US20040204378A1 (2004).
125. Rothstein DM, McGlynn M, Bernan V, et al. Detection of tetracyclines and efflux pump inhibitors. Antimicrob Agents Chemother 1993; 37: 1624-1629.
126. Fournier dit Chabert J, Marquez B, Neville L, et al. Synthesis and evalutation of new arylbenzo[b]thiophene and diarylthiophene derivatives as inhibitors of the NorA multidrug transporter of S. aureus. J Biorg Med Chem 2007; 18: 4482-4497.
127. Markham PN, Westhaus E, Klyachko K, Johnson ME, Neyfakh AA. Multiple novel inhibitors of the NorA multidrug trasnporter of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 2404-2408.
128. Ambrus JI, Kelso MJ, Bremner JB, Ball AR, Casadei G, Lewis K. Structure-activity relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pumps in S. aureus. Bioorg Med Chem Lett 2008; 18: 4294-4297.
129. Sudeno Roccaro A, Blanco AR, Giuliano F, Rusciano D, Enea V. Epigallocaechin-gallate enhances the activity of tetracyclines in staphylococci by inhibiting its efflux from bacterial cells. Antimicrob Agents Chemother 2004; 48: 1968-1973.
130. Gibbons S, Moser E, Kaatz GW. Catechingallates inhibit multidrug resistance (MDR) in Staphylococcus aureus. Plante Med 2004; 70: 1240-1242.
131. Gibbons S, Oluwatuyi M, Kaatz GW. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 13-17.
132. Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother 2004; 48: 4171-4176.
133. Fais, S., Luciani, F.: US20080160106 (2008).
134. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006; 443: 173-179.
135. Seeger MA, Diederichs K, Eicher T, et al. The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance. Curr Drug Targets 2008; 9: 729-749.
136. Nargotra A, Koul S, Sharma S, et al. Quantitative-structure-activity relationship (QSAR) of aryl alkenyl amides/imines for bacterial efflux pump inhibitors. Eur J Med Chem 2008 (in press) doi: 10.1016/ejmche.2008.02.015.
137. Ahmed M, Borsch C, Neyfakh A, Schuldner S. Mutants of Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. J Biol Chem 1993; 268: 11086-11089.
138. Klyachko KA, Schuldiner S, Neyfakh AA. Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter BMR J Bacteriol 1997; 179: 2189-2193.
139. Garvey MI, Piddock LSV. The efflux pump inhibitor reserpine selects multidrug resistant S. pneumoniae strains that overexpress the ABC transporters PatA and PatB. Antimicrob Agents Chemother 2008; 52: 1677-1685.